Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Palvella Therapeutics Inc (PVLA)

Palvella Therapeutics Inc (PVLA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,556,552
  • Shares Outstanding, K 11,836
  • Annual Sales, $ 0 K
  • Annual Income, $ -17,430 K
  • EBIT $ -29 M
  • EBITDA $ -27 M
  • 60-Month Beta -0.30
  • Price/Sales -31,131.04
  • Price/Cash Flow N/A
  • Price/Book 37.92

Options Overview Details

View History
  • Implied Volatility 80.19% (-0.96%)
  • Historical Volatility 120.54%
  • IV Percentile 47%
  • IV Rank 7.51%
  • IV High 246.56% on 02/17/26
  • IV Low 66.67% on 12/18/25
  • Expected Move (DTE 16) 15.05 (11.10%)
  • Put/Call Vol Ratio 1.57
  • Today's Volume 54
  • Volume Avg (30-Day) 280
  • Put/Call OI Ratio 1.68
  • Today's Open Interest 4,169
  • Open Int (30-Day) 3,750
  • Expected Range 120.45 to 150.54

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.95
  • Number of Estimates 6
  • High Estimate -0.87
  • Low Estimate -1.03
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.10%

Price Performance

See More
Period Period Low Period High Performance
1-Month
74.40 +82.11%
on 02/05/26
151.18 -10.38%
on 02/26/26
+53.48 (+65.21%)
since 02/04/26
3-Month
72.22 +87.59%
on 01/30/26
151.18 -10.38%
on 02/26/26
+41.69 (+44.45%)
since 12/04/25
52-Week
18.23 +643.43%
on 04/09/25
151.18 -10.38%
on 02/26/26
+114.79 (+554.54%)
since 03/04/25

Most Recent Stories

More News
Palvella Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares

WAYNE, Pa., March 02, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (“Palvella”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel...

PVLA : 135.49 (+3.03%)
Palvella Therapeutics Announces Pricing of Upsized Public Offering

WAYNE, Pa., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (“Palvella”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies...

PVLA : 135.49 (+3.03%)
Stocks Settle Higher as AI Disruption Fears Ease

The S&P 500 Index ($SPX ) (SPY ) on Tuesday closed up +0.77%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up +0.76%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +1.09%. March E-mini...

AMAT : 357.76 (+1.83%)
HSIC : 80.58 (+0.46%)
DDOG : 118.33 (+5.87%)
EXPD : 146.85 (-0.80%)
TRI : 104.82 (-0.61%)
$IUXX : 25,093.68 (+1.51%)
BWXT : 205.57 (-0.13%)
ASML : 1,399.37 (+2.82%)
ZNM26 : 112-185 (-0.21%)
ESH26 : 6,866.00 (-0.15%)
QCOM : 139.51 (+1.00%)
KEYS : 300.92 (-0.54%)
Palvella Therapeutics Announces Proposed Public Offering

WAYNE, Pa., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (“Palvella”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies...

PVLA : 135.49 (+3.03%)
Stocks Rally as AI-Fueled Worries Ease

The S&P 500 Index ($SPX ) (SPY ) today is up +0.50%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.75%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.90%. March E-mini S&P futures (ESH26...

INTU : 440.14 (+1.57%)
HSIC : 80.58 (+0.46%)
ADI : 341.51 (+0.74%)
EXPD : 146.85 (-0.80%)
TRI : 104.82 (-0.61%)
TXN : 202.39 (-0.14%)
$IUXX : 25,093.68 (+1.51%)
BWXT : 205.57 (-0.13%)
ZNM26 : 112-185 (-0.21%)
ESH26 : 6,866.00 (-0.15%)
FANG : 176.71 (-0.46%)
QCOM : 139.51 (+1.00%)
Stocks Rebound as Software Stocks Recover

The S&P 500 Index ($SPX ) (SPY ) today is up +0.17%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.64%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.47%. March E-mini S&P futures (ESH26...

INTU : 440.14 (+1.57%)
HSIC : 80.58 (+0.46%)
HIMS : 16.45 (+3.98%)
DDOG : 118.33 (+5.87%)
EXPD : 146.85 (-0.80%)
PAY : 25.34 (-1.13%)
$IUXX : 25,093.68 (+1.51%)
BWXT : 205.57 (-0.13%)
ZNM26 : 112-185 (-0.21%)
ESH26 : 6,866.00 (-0.15%)
QCOM : 139.51 (+1.00%)
KEYS : 300.92 (-0.54%)
Palvella Therapeutics Announces Positive Topline Results from Phase 3 SELVA Clinical Study of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) in Microcystic Lymphatic Malformations

Primary endpoint met with statistically significant improvement (mean change of +2.13; p

PVLA : 135.49 (+3.03%)
Palvella Therapeutics to Host Conference Call to Discuss Topline Results from Phase 3 SELVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) in Microcystic Lymphatic Malformations 

WAYNE, Pa., Feb. 23, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA)  Palvella Therapeutics , Inc. (Palvella or “the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing...

PVLA : 135.49 (+3.03%)
Palvella Therapeutics Announces Scientific Publication in Clinical and Experimental Dermatology Highlighting a Systematic Review of Real-World Statin Evidence and Persistent Treatment Gaps Resulting from the Lack of FDA-Approved Therapies in...

Publication includes a systematic review of 24 studies describing off-label cutaneous application of statins in porokeratosis   Preliminary case reports suggesting clinical benefit underscore...

PVLA : 135.49 (+3.03%)
Palvella Therapeutics Provides Corporate Update and 2026 Outlook: Advancing a Late Clinical-Stage Pipeline and Platform to Address Multiple Serious, Rare Skin Diseases and Vascular Malformations with No FDA-Approved Therapies

Phase 3 SELVA study evaluating QTORIN™ rapamycin 3.9% anhydrous gel (QTORIN™ rapamycin) for microcystic lymphatic malformations (microcystic LMs) remains on track, with topline results anticipated...

PVLA : 135.49 (+3.03%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Palvella Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc., formerly known as Pieris Pharmaceuticals Inc., is based in WAYNE, Pa.

See More

Key Turning Points

3rd Resistance Point 146.29
2nd Resistance Point 142.14
1st Resistance Point 138.82
Last Price 135.49
1st Support Level 131.35
2nd Support Level 127.20
3rd Support Level 123.88

See More

52-Week High 151.18
Last Price 135.49
Fibonacci 61.8% 100.39
Fibonacci 50% 84.70
Fibonacci 38.2% 69.01
52-Week Low 18.23

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar